Finding new osteoarthritis medicines via AI and genetics

Osteoarthritis, or OA, is a chronic and painful joint disease that is the leading cause of disability. Currently, treatments for OA are limited and mainly focus on managing symptoms. A research team from the University of Utah is using cutting-edge genetic and artificial intelligence technologies to discover new drugs that may treat OA at its source.

By analyzing genetic data from Utah families with hereditary OA, the researchers discovered that a gene called WNK2 plays a crucial role in the disease's progression. In families affected by this form of OA, overactivity of the WNK2 gene triggers inflammatory processes in joint cells.

To find a potential drug target, the scientists employed an AI-based tool to predict the structure of the WNK2 protein. Using this information, they computationally simulated how thousands of chemical compounds would interact with WNK2, narrowing down a pool of half a million drug candidates to just six.

One of the promising compounds, designated M04, appeared to prevent OA-related changes and promote cell health in a model of osteoarthritis based on human cartilage cells. M04 not only inhibited inflammatory genes associated with OA but also increased the expression of genes that promote cellular health.

While M04 shows promise as a potential OA drug, further research is needed to determine its safety and efficacy in living organisms. The team is collaborating with the University of Utah Therapeutics Accelerator Hub to develop improved derivatives of M04 and to test its safety and efficacy in animal models before considering clinical trials.

This discovery marks the beginning of a promising new approach to OA treatment, providing a valuable starting point for the development of more effective drugs to combat this debilitating disease.